ea0031oc5.6 | Pituitary and neoplasia | SFEBES2013
Smith Vicki
, Sharma Neil
, Read Martin
, Ryan Gavin
, Kwan Perkin
, Turnell Andrew
, Martin Ashley
, Boelaert Kristien
, Franklyn Jayne
, McCabe Christopher
The clinical effectiveness of ablative radioiodine treatment is limited by the ability of the sodium iodide symporter (NIS) to uptake 131I. A significant proportion of well-differentiated thyroid tumours are unable to concentrate sufficient radioiodine for effective therapy, and in other tumour models such as breast, where radioiodine uptake would be an attractive therapeutic option, uptake is insufficient. Pituitary tumor-transforming gene-binding factor (PBF/ PTTG...